

# 1 **MUTATE: A Human Genetic Atlas of Multi-organ AI** 2 **Endophenotypes using GWAS Summary Statistics**

3  
4 Junhao Wen<sup>1\*</sup>, Christos Davatzikos<sup>2</sup>, Jian Zeng<sup>3</sup>, Li Shen<sup>4</sup>, Andrew Zalesky<sup>5</sup>, Ye Ella Tian<sup>5</sup>,  
5 Zhijian Yang<sup>2</sup>, Aleix Boquet-Pujadas<sup>7</sup>

6  
7 <sup>1</sup>Laboratory of AI and Biomedical Science (LABS), University of Southern California, Los Angeles, California,  
8 USA

9 <sup>2</sup>Artificial Intelligence in Biomedical Imaging Laboratory (AIBIL), Center for AI and Data Science for Integrated  
10 Diagnostics (AI<sup>2</sup>D), Perelman School of Medicine, University of Pennsylvania, Philadelphia, USA

11 <sup>3</sup>Institute for Molecular Bioscience, University of Queensland, Brisbane, QLD 4072, Australia

12 <sup>4</sup>Department of Biostatistics, Epidemiology and Informatics, University of Pennsylvania Perelman School of  
13 Medicine, Philadelphia, PA, USA

14 <sup>5</sup>Melbourne Neuropsychiatry Centre, Department of Psychiatry, Melbourne Medical School, The University of  
15 Melbourne, Melbourne, Victoria, Australia

16 <sup>6</sup>Biomedical Imaging Group, EPFL, Lausanne, Switzerland

17  
18 \*Corresponding authors:

19 Junhao Wen, [junhaowe@usc.edu](mailto:junhaowe@usc.edu)


20 2025 Zonal Ave, Los Angeles, CA 90033, United States

21

## 22 **Highlight**

- 23 • Two AI- and neuroimaging-derived subtypes of schizophrenia (SCZ1 and SCZ2) show  
24 lower polygenicity and weaker negative selection signatures than the disease  
25 endpoint/diagnosis of schizophrenia, supporting the endophenotype hypothesis.
- 26 • Brain AI endophenotypes are more polygenic than other organ systems.
- 27 • Most multi-organ AI endophenotypes exhibit negative selection signatures, whereas a  
28 small proportion of brain patterns of structural covariance networks exhibit positive  
29 selection signatures.
- 30 • The 2024 multi-organ AI endophenotypes are genetically and causally associated with  
31 within-organ and cross-organ disease endpoints/diagnoses.

## 32 Graphical abstract



33

34 **Keywords**

35 Multi-organ AI endophenotypes, genetic correlation, Mendelian randomization, polygenic risk  
36 score

37

## 38 **Summary**

39 Artificial intelligence (AI) has been increasingly integrated into imaging genetics to provide  
40 intermediate phenotypes (i.e., endophenotypes) that bridge the genetics and clinical  
41 manifestations of human disease. However, the genetic architecture of these AI endophenotypes  
42 remains largely unexplored in the context of human multi-organ system diseases. Using publicly  
43 available GWAS summary statistics from UK Biobank, FinnGen, and the Psychiatric Genomics  
44 Consortium, we comprehensively depicted the genetic architecture of 2024 multi-organ AI  
45 endophenotypes (MAEs). Two AI- and imaging-derived subtypes<sup>1</sup> showed lower polygenicity  
46 and weaker negative selection effects than schizophrenia disease diagnoses<sup>2</sup>, supporting the  
47 endophenotype hypothesis<sup>3</sup>. Genetic correlation and Mendelian randomization results  
48 demonstrate both within-organ connections and cross-organ talk. Bi-directional causal  
49 relationships were established between chronic human diseases and MAEs across multiple organ  
50 systems, including Alzheimer's disease for the brain, diabetes for the metabolic system, asthma  
51 for the pulmonary system, and hypertension for the cardiovascular system. Finally, we derived  
52 the polygenic risk scores of the 2024 MAEs. Our findings underscore the promise of the MAEs  
53 as new instruments to ameliorate overall human health. All results are encapsulated into the  
54 MUTATE genetic atlas and are publicly available at <https://labs-laboratory.com/mutate>.

## 55 Introduction

56 Multi-organ research<sup>1,4-11</sup> represents a pivotal frontier in advancing our understanding of human  
57 aging and disease. In particular, integrating artificial intelligence (AI) into multi-organ imaging  
58 genetics<sup>1,4,12,6</sup> has emerged as a novel approach, offering potential promise in advancing  
59 precision medicine<sup>13</sup>. This integration introduces a new array of endophenotypes<sup>14,15</sup>, serving as  
60 intermediate, often quantitative, phenotypes, potentially reshaping how we perceive and  
61 approach medical AI<sup>16</sup> in imaging and genetic research.

62 In recent years, three primary catalysts have significantly advanced the field of genetics.  
63 The first pivotal factor stems from the extensive collaborative efforts in consolidating large-scale  
64 multi-omics datasets, which has endowed researchers with unprecedented statistical power  
65 previously inaccessible. As an illustration, the UK Biobank (UKBB) study<sup>17</sup> stands out for its  
66 comprehensive collection of multi-organ imaging<sup>18</sup>, genetics<sup>19</sup>, and proteomics<sup>20,21</sup> data within  
67 the United Kingdom. Similarly, the FinnGen study<sup>22</sup>, conducted in Finland, has amassed  
68 extensive clinical and genetic data. Secondly, efforts toward open science have propelled the  
69 field, especially emphasizing the significance of publicly available resources, such as genome-  
70 wide association study (GWAS) summary statistics and widespread scientific dissemination.  
71 Notably, the FinnGen study and Psychiatric Genomics Consortium (PGC<sup>23</sup>) have publicly made  
72 all the GWAS summary statistics accessible<sup>22</sup>. Public GWAS platforms such as the GWAS  
73 Catalog<sup>24</sup>, OpenGWAS<sup>25</sup>, and GWAS ATLAS<sup>26</sup> have consolidated and harmonized vast GWAS  
74 datasets, rendering them suitable for subsequent genetic analyses. Likewise, such good practice  
75 was also employed in the newly burgeoning field of brain imaging genetics<sup>27</sup>, including the  
76 BIG40 (<https://open.win.ox.ac.uk/ukbiobank/big40/>), the BIG-KP (<https://bigkp.org/>),  
77 BRIDGEPORT (<https://labs-laboratory.com/bridgeport>), and MEDICINE (<https://labs-laboratory.com/medicine>)  
78 knowledge portals. Finally, advanced computational genomics  
79 statistical methods using solely GWAS summary statistics, along with sufficient linkage  
80 disequilibrium information, have been developed, presenting an unparalleled chance to  
81 comprehend the genetic architecture of highly polygenic disease traits. For example, LDSC<sup>28</sup> has  
82 been extensively utilized to estimate single-nucleotide polymorphism (SNP)-based heritability  
83 and genetic correlations. Mendelian randomization<sup>29</sup> is a statistical method to dissect associations  
84 further, probing potential causal relationships among these complex human disease traits,  
85 although these methods often rely on several sensitive model assumptions<sup>30</sup>.

86 Despite these advancements, the intricate genetic foundation shaping these AI  
87 endophenotypes in the context of pleiotropic human disease endpoints (DE) within multi-organ  
88 systems remains largely uncharted. We previously applied AI to imaging genetic data and  
89 derived 2024 multi-organ AI endophenotypes (MAE). These encompassed 2003 multi-scale  
90 brain patterns of structural covariance (PSC) networks generated through a deep learning-  
91 analogy non-negative matrix factorization method<sup>12</sup> (visualization for C32\_1 encompassing deep  
92 subcortical structures: [https://labs-laboratory.com/bridgeport/MuSIC/C32\\_1](https://labs-laboratory.com/bridgeport/MuSIC/C32_1)), 9 dimensional  
93 neuroimaging endophenotypes (DNE) quantifying neuroanatomical heterogeneity (also known as  
94 disease subtype) within 4 common brain diseases<sup>7</sup>, and 12 biological age gap (BAG) assessing  
95 the individual deviation in typical aging (i.e., acceleration or deceleration from the chronological  
96 age) across 9 human organ systems<sup>4,6</sup> (**Supplementary eTable 1a**). To contribute to open  
97 science<sup>31</sup>, we made all the GWAS summary statistics derived from UKBB data publicly  
98 available at the MEDICINE knowledge portal: <https://labs-laboratory.com/medicine>. In addition,  
99 FinnGen analyzed genetic data for 2269 binary and 3 quantitative DEs from 377,277 individuals  
100 and 20,175,454 variants. They made these massive GWAS summary statistics publicly available

101 to the community at <https://finngen.gitbook.io/documentation/> (**Supplementary eTable 1b**).  
102 Finally, PGC consolidated GWAS results focused on neurological disorders worldwide and  
103 made the GWAS summary statistics accessible to the research community (<https://pgc.unc.edu/>,  
104 **Supplementary eTable 1c**).

105 This study harnesses the extensive GWAS summary resources made publicly available  
106 by us on behalf of UKBB, FinnGen, and PGC (**Method 1**), along with the utilization of several  
107 advanced computational genomics statistical methods (refer to **Code Availability**), to thoroughly  
108 depict the genetic architecture of the 2024 MAEs (**Method 2**) and 525 DEs (>5000 cases) in the  
109 context of multi-organ investigations. Importantly, our previous research explored the genetic  
110 foundation of the 2024 MAEs but did not systematically encompass the FinnGen or PGC data.  
111 Specifically, we included 521 DEs released by the FinnGen study, accessible at  
112 <https://finngen.gitbook.io/documentation/v/r9/>, and 4 brain DEs (Alzheimer’s disease (AD),  
113 Attention-deficit/hyperactivity disorder (ADHD), bipolar disorder (BIP), and schizophrenia  
114 (SCZ)) from PGC (<https://pgc.unc.edu/>). This study expanded on this by systematically  
115 benchmarking the genetic analyses and comprehensively comparing various statistical  
116 methodologies<sup>28,30,32–38</sup> (**Method 3**). Specifically, we aimed to compute the SNP-based  
117 heritability ( $h_{SNP}^2$ ), polygenicity ( $\pi$ ), the relationship between SNP effect size and minor allele  
118 frequency ( $S$ : signature of natural selection, genetic correlation ( $r_g$ ), causality, and polygenic risk  
119 score (PRS) between the 2024 MAEs and 525 DEs. These findings were encapsulated within the  
120 MUTATE (**MUITi-organ AI endophenoTypeE**) genetic atlas, which is publicly available at  
121 <https://labs-laboratory.com/mutate>.

## 122 Results

### 123 The genetic architecture of the 2024 MAEs and 525 DEs

124 We computed three parameters to fully depict the genetic architecture of the 2024 MAEs  
125 (**Method 3a**). For the SNP-based heritability ( $h_{SNP}^2$ ), SBayesS<sup>39</sup> obtained the highest  $h_{SNP}^2$  for the  
126 2016 brain MAEs (mean  $\hat{h}_{SNP}^2=0.13$  [0.01, 0.38]), followed by the pulmonary BAG  
127 ( $0.16\pm 0.004$ ), the eye BAG ( $0.14\pm 0.009$ ), the cardiovascular BAG ( $0.12\pm 0.003$ ), the renal BAG  
128 ( $0.10\pm 0.003$ ), and the musculoskeletal BAG ( $0.10\pm 0.003$ ) (**Fig. 1a** and **Supplementary eFile 1**).  
129 It is worth noting that SNP-based heritability varies across methods and depends on the input  
130 data, i.e., summary data or individual-level genotype data used in the method<sup>40</sup>. We aimed to  
131 benchmark the summary data-based methods by comparing the results from SBayesS with those  
132 of LDSC<sup>28</sup> and SumHer<sup>33</sup>. Overall, while the estimates from the three methods were highly  
133 correlated ( $r=0.97$  between LDSC and SumHer;  $r=0.99$  between SBayesS and SumHer;  $r=0.99$   
134 between SBayesS and LDSC; **Supplementary eFigure 1**), SumHer ( $0.23\pm 0.14$ ) generally  
135 yielded larger  $h_{SNP}^2$  estimates than both LDSC ( $0.16\pm 0.10$ ) and SBayesS ( $0.13\pm 0.08$ )  
136 (**Supplementary eFile 1**). We present the  $h_{SNP}^2$  estimate of the 525 DEs and 2024 MAEs in  
137 **Supplementary eFigure 2**. **Supplementary eFile 2** presents the results of the 525 DEs. For the  
138 525 DEs, we converted the  $h_{SNP}^2$  estimates from the observed scales to the liability scales,  
139 following the recommendations of Ojavee et al<sup>41</sup>. It's important to clarify that we did not intend  
140 to compare the  $h_{SNP}^2$  estimates of the two data sources due to differences in genotype coverage,  
141 sample sizes, allele frequencies, and other factors.

142 We then computed the natural selection signature ( $S$ ) for the 2024 MAEs. The metabolic  
143 BAG showed a strong negative selection ( $S=-0.82\pm 0.10$ ), followed by the pulmonary BAG ( $S=-$   
144  $0.79\pm 0.05$ ), the hepatic BAG ( $S=-0.74\pm 0.09$ ), the renal BAG ( $S=-0.68\pm 0.08$ ), and the immune  
145 BAG ( $S=-0.66\pm 0.11$ ). For the brain MAEs ( $S=-0.33$  [-1, 0.43]), the brain BAG and ( $S=-$   
146  $0.70\pm 0.12$ ) the subtype (ASD1) for autism spectrum disorder<sup>42</sup> ( $S=-0.90\pm 0.11$ ) showed strong  
147 negative selection effects (**Fig. 1b** and **Supplementary eFile 3**).


148 Finally, we calculated the polygenicity ( $\pi$ ) for the 2024 MAEs. We found that brain  
149 MAEs ( $0.040$  [0.003, 0.072]) showed higher polygenicity than other organ systems, followed by  
150 the pulmonary BAG ( $0.018\pm 0.001$ ), the musculoskeletal BAG ( $0.013\pm 0.001$ ), and the  
151 cardiovascular BAG ( $0.011\pm 0.001$ ) (**Fig. 1C** and **Supplementary eFile 4**). The PSC (C128\_115:  
152 [https://labs-laboratory.com/bridgeport/MuSIC/C128\\_115](https://labs-laboratory.com/bridgeport/MuSIC/C128_115)) showed the highest polygenicity  
153 estimate ( $0.072\pm 0.002$ ).

### 155 Supporting evidence for the endophenotype hypothesis

156 Previous studies<sup>43,44</sup> have found supporting evidence for the endophenotype hypothesis<sup>14,15</sup> using  
157 traditional brain map-based signatures, showing that more genes are associated with disease  
158 endpoints than imaging-derived signatures (i.e., endophenotypes). Of note, considering genetic  
159 differences between FinnGen and UKBB samples, SBayesS with the UKBB as LD reference  
160 may give biased estimates of  $S$  and  $\pi$  (LD from FinnGen not fully available; **Method 3a**).  
161 Therefore, we used the GWAS summary data for PGC schizophrenia (SCZ<sup>2</sup>) and two subtypes  
162 of SCZ (SCZ1 and SCZ2<sup>1</sup>) from our UKBB analysis to demonstrate this. The advantage of using  
163 PGC data is that the GWAS summary statistics are better powered (large sample sizes), and the  
164 data were from European ancestry groups across different countries. A data harmonization  
165 procedure is outlined in **Supplementary eMethod 1** to ensure a fair comparison of these  
166 estimates, which led to the utilization of a common set of SNPs and linkage disequilibrium



167 information for computing the  $S$  and  $\lambda$  parameters. Our results showed that SCZ1  
 168 ( $\lambda = 0.048 \pm 0.002$ ;  $S = -0.61 \pm 0.09$ ) and SCZ2 ( $\lambda = 0.047 \pm 0.002$ ;  $S = -0.54 \pm 0.12$ ) had lower  
 169 polygenicity signals and weaker negative selection effects than SZC ( $\lambda = 0.055 \pm 0.003$ ;  $S = -$   
 170  $0.82 \pm 0.04$ ) (**Fig. 1d**). **Supplementary eFigure 3** shows the Manhattan plot of the harmonized  
 171 summary data for SCZ1, SCZ2, and SZC. These findings support the endophenotype  
 172 hypothesis<sup>3</sup>, which suggests that intermediate phenotypes (such as SCZ subtype MAEs) are part  
 173 of the causal pathway from genetics to exo-phenotypes (such as SCZ binary diagnosis), making  
 174 them closer to the underlying etiology. Consequently, the SCZ subtypes were found to be less  
 175 polygenic<sup>43,44</sup>.



176  
 177 **Figure 1: The genetic architecture of the 2024 MAEs**  
 178 Three parameters are estimated by SBayesS to delineate the genetic architecture of the 2024  
 179 MAEs, including (a) the SNP-based heritability ( $\lambda$ ), (b) the relationship between MAF and  
 180 effect size ( $S$ ), and (c) polygenicity ( $\lambda$ ). (d) We compared the  $\lambda$  and  $S$  parameters using  
 181 harmonized GWAS summary data for two AI- and imaging-derived subtypes (SCZ1 and SCZ2<sup>1</sup>)  
 182 from UKBB and the disease endpoint of schizophrenia (SCZ<sup>2</sup>) from PGC. FinnGen data was not  
 183 used due to bias stemming from the unavailability of FinnGen-specific linkage disequilibrium  
 184 data (**Supplementary eMethod 1**). We present the distribution of the estimated parameters for  
 185 the 2016 brain MAEs using a violin plot; the mean value is denoted by the black horizontal line.  
 186


187 **The genetic correlation shows organ-specific and cross-organ associations**

188 We found 132 ( $P$ -value  $< 0.05/2024$ ) and 45 ( $P$ -value  $< 0.05/2024/525$ ) commonly significant  
 189 positive genetic correlations ( $r_g$ ) after applying two levels of Bonferroni correction (**Fig. 2**) for  
 190 the LDSC<sup>28</sup> and GNOVA<sup>34</sup> methods (**Method 3b, Supplementary eFile 5, and Supplementary**

191 **eTable 2).** We noted that HDL encountered convergence issues with the models, as detailed in  
192 **Method 3b.**

193 Between these methods, the magnitude of the genetic correlations for the significant  
194 signals for both methods differed: mean  $\hat{r}_g=0.24[-0.40\sim-0.52]$  with 213 significant signals for  
195 LDSC, mean  $\hat{r}_g=0.17[-0.30\sim-0.62]$  for GNOVA with 428 significant signals (**Fig. 2**). The three  
196 sets of converged estimates showed a strong correlation:  $r=0.77$  (P-value $<1\times 10^{-10}$ ;  $N=1,062,577$ )  
197 between LDSC and GNOVA,  $r=0.81$  (P-value $<1\times 10^{-10}$ ;  $N=59,289$ ) between LDSC and HDL,  
198 and  $r=0.82$  (P-value $<1\times 10^{-10}$ ;  $N=59,289$ ) between GNOVA and HDL. **Supplementary eFigure**  
199 **4** shows the correlation of the three sets of estimates.

200 Within the significant signals identified, we observed *i*) organ-specific associations, in  
201 which the MAE showed a genetic association with the DE originating from the respective organ  
202 system, and *ii*) cross-organ connections, in which the MAE and DE were primarily involved  
203 from different organ systems. For example, two brain PSCs showed significant negative genetic  
204 correlations with BIP from PGC (C512\_368 vs. BIP:  $-0.16\pm 0.03$ ; C1024\_114 vs. BIP: -  
205  $0.15\pm 0.03$ ). At a less stringent level, the brain MAEs were also genetically associated with DEs  
206 from other organ systems, including the positive correlation between C1024\_808 and obesity  
207 (E4\_OBESITY:  $r_g=0.17\pm 0.13$ ). The cardiovascular BAG was positively correlated with several  
208 DEs related to the cardiovascular system, including ischemic heart disease (I9\_IHD:  
209  $r_g=0.26\pm 0.03$ ), coronary heart disease (I9\_HEARTFAIL\_AND\_CHD:  $r_g=0.26\pm 0.03$ ), angina  
210 (I9\_ANGINA:  $r_g=0.25\pm 0.03$ ) and atrial fibrillation (I9\_AF:  $r_g=0.22\pm 0.04$ ). Likewise, the  
211 pulmonary BAG was positively associated with multiple DEs related to the lung and respiratory  
212 system, including chronic obstructive pulmonary disease (COPD\_EARLY:  $r_g=0.47\pm 0.04$ ) and  
213 various forms of asthma (ASTHMA\_NAS:  $r_g=0.43\pm 0.04$ ). Cross-organ connections were  
214 established, such as between the pulmonary BAG and substance abuse  
215 (KRA\_PSY\_SUBSTANCE\_EXMORE:  $r_g=0.20\pm 0.03$ ) and hypertension (I9\_HYPTENS:  
216  $r_g=0.17\pm 0.03$ ). Lastly, the metabolic BAG was largely linked to different forms of diabetes  
217 (T2D:  $r_g=0.40\pm 0.04$ ).



218  
219  
220  
221  
222

**Figure 2: Genetic correlation between the 2024 MAEs and 525 DEs**  
The significant genetic correlation estimates ( $r_g$ ) between 2024 MAEs and 525 DEs are depicted, considering two levels of corrections for multiple comparisons, considering the relatively smaller sample sizes (<40,000) for brain MAEs compared to other organ MAEs (>100,000). Initially, we


223 reveal significant results shared between LDSC and GNOVA, employing Bonferroni correction  
224 based solely on the number of MAEs (P-value<0.05/2024), uncovering 133 MAE-AE pairs.  
225 Subsequently, a stricter correction based on both the number of MAEs and DEs is applied,  
226 leading to 45 unique MAE-AE pairs marked as red squares; the numeric results are displayed  
227 using results from LDSC. The genetic correlation for non-significant results was set to 0 for  
228 visualization purposes. For the MAEs, readers can explore the BRIDGEPORT portal for a visual  
229 representation of the 2003 brain PSCs (e.g., C256\_225: [https://labs-](https://labs-laboratory.com/bridgeport/MuSIC/C256_225)  
230 [laboratory.com/bridgeport/MuSIC/C256\\_225](https://labs-laboratory.com/bridgeport/MuSIC/C256_225)) and the other BAGs at the MEDICINE portal:  
231 <https://labs-laboratory.com/medicine>.

### 232 233 **The brain, cardiovascular, and pulmonary MAEs are causally linked to DEs of multiple** 234 **organ systems**

235 Employing five distinct two-sample Mendelian randomization estimators, we identified 39 (P-  
236 value<0.05/633) and 15 (P-value<0.05/633/524) significant causal relationships, directed from  
237 the MAE to DE, that withstood the Bonferroni correction at two different levels of rigors, as per  
238 the inverse variance weighted (IVW) estimator and at least one of the other four estimators  
239 (**Method 3c** and **Supplementary eTable 3**).

240 Within the 15 significant causal relationships, the brain MAEs showed causal  
241 connections with DEs from the brain, as well as DEs from other organ systems. For example, the  
242 brain PSC (C1024\_598) was causally linked to SCZ from PGC [P-value=9.89x10<sup>-8</sup>; OR (95%  
243 CI)=0.69 (0.59, 0.79); the number of IVs=7]. C1024\_684 was causally linked to Ventral hernia  
244 from FinnGen [K11\_VENTHER: P-value=1.09x10<sup>-7</sup>; OR (95% CI)=1.43 (1.25, 1.63); the  
245 number of IVs=18]. The pulmonary BAG was causally linked to multiple DEs related to the  
246 pulmonary system, including chronic obstructive pulmonary disease (COPD) [J10\_COPD: P-  
247 value=2.70x10<sup>-20</sup>; OR (95% CI)=1.77 (1.56, 2.00); the number of IVs=59] and asthma  
248 [ASTHMA\_PNEUMONIA: P-value=1.51x10<sup>-14</sup>; OR (95% CI)=1.67 (1.41, 1.96); the number of  
249 IVs=59]. The cardiovascular BAG was causally linked to ischemic heart disease (IHD)  
250 [ASTHMA\_PNEUMONIA: P-value=1.09x10<sup>-7</sup>; OR (95% CI)=1.64 (1.36, 1.96); the number of  
251 IVs=37] (**Fig. 3**). The quality check of the significant signals is presented in **Supplementary**  
252 **eFolder 1. Supplementary eFile 6** presents the full set of results for the 521 FinnGen DEs and 4  
253 PGC DEs.

254  
255



**Figure 3: Causal relationship from the 2024 MAEs to the 525 DEs**

The causal relationship from the 2024 MAEs to the 525 DEs revealed 39 significant MAE-DE pairs, involving 633 MAEs as effective exposure variables (>8 instrumental variables before harmonization) and 525 DEs as outcomes. Bonferroni correction was applied to identify potential significant causal signals based on *i*) the 633 MAEs ( $P\text{-value} < 0.05/633$ ) and *ii*) the 633 MAEs and 525 DEs ( $P\text{-value} < 0.05/633/524$ , denoted by the 15 red rectangles). Furthermore, we verified that the statistical significance attained for the IVW estimator was consistent and persisted across at least one of the other four Mendelian randomization estimators (Egger, weighted median, simple mode, and weighted mode estimators). For visualization purposes, the odds ratios for non-significant results were set to 1 and were left blank. For the MAEs, readers can explore the BRIDGEPORT portal for a visual representation of the 2003 brain PSCs (e.g., C32\_4: [https://labs-laboratory.com/bridgeport/MuSIC/C32\\_4](https://labs-laboratory.com/bridgeport/MuSIC/C32_4)) and the other BAGs at the MEDICINE portal: <https://labs-laboratory.com/medicine>.


### The DEs involving Alzheimer’s disease, diabetes, asthma, and hypertension exert causal effects on multi-organ MAEs

We then tested the inverse causality by employing the DEs as exposure and MAEs as outcome variables. We identified 47 ( $P\text{-value} < 0.05/787$ ) and 23 ( $P\text{-value} < 0.05/787/214$ ) significant causal relationships, directed from the DE to MAE, that survived the Bonferroni correction at two different levels of rigors (**Method 3c** and **Supplementary eTable 4**).

Within the 23 significant causal relationships ( $P\text{-value} < 0.05/787/214$ ), various forms of Alzheimer’s disease were linked to the brain MAEs, including the brain BAG [G6\_AD\_WIDE:  $P\text{-value} = 3.03 \times 10^{-7}$ ; OR (95% CI) = 1.10 (1.06, 1.13); the number of IVs = 8] and metabolic BAG [G6\_AD\_WIDE:  $P\text{-value} = 3.03 \times 10^{-7}$ ; OR (95% CI) = 1.07 (1.04, 1.09); the number of IVs = 8]. Type 1 diabetes (E4\_DM1NASCOMP) was also causally linked to multiple brain PSCs. In addition, the cardiovascular BAG was causally linked to multiple heart diseases, including hypertension [I9\_HYPTENS:  $P\text{-value} = 4.67 \times 10^{-31}$ ; OR (95% CI) = 1.23 (1.19, 1.27); the number of IVs = 110]. Several forms of asthma were causally linked to the pulmonary BAG, such as allergic asthma [ALLERG\_ASTHMA:  $P\text{-value} = 2.38 \times 10^{-9}$ ; OR (95% CI) = 1.09 (1.06, 1.13); the number of IVs = 14]. Finally, obesity was also linked to the renal BAG [E4\_OBESITY:  $P\text{-value} = 2.74 \times 10^{-8}$ ; OR (95% CI) = 1.11 (1.07, 1.15); the number of IVs = 19] (**Fig. 4**).



288 **Supplementary eFolder 2** presents the quality check results of the significant signals.  
 289 **Supplementary eFile 7** presents the full set of results for the 521 FinnGen DEs and 4 PGC DEs.  
 290




291 **Figure 4: Causal relationship from the 525 DEs to the 2024 MAEs**  
 292 The causal relationship from the 525 MAEs to the 2024 DEs revealed 47 significant DE-MAE  
 293 pairs, involving 214 DEs as effective exposure variables (>8 instrumental variables before  
 294 harmonization) and 787 DEs as effective outcomes after quality checks. Bonferroni correction  
 295 was applied to identify potential significant causal signals based on *i*) the 787 MAEs (P-  
 296 value<0.05/787) and *ii*) the 787 MAEs and 214 DEs (P-value<0.05/787/214, denoted by the 23  
 297 red rectangles). Furthermore, we verified that the statistical significance attained for the IVW  
 298 estimator was consistent and persisted across at least one of the other four Mendelian  
 299 randomization estimators (Egger, weighted median, simple mode, and weighted mode  
 300 estimators). For visualization purposes, the odds ratios for non-significant results were set to 1  
 301 and were left blank. For the MAEs, readers can explore the BRIDGEPORT portal for a visual  
 302 representation of the 2003 brain PSCs (e.g., C128\_13: [https://labs-  
 303 laboratory.com/bridgeport/MuSIC/C128\\_13](https://labs-laboratory.com/bridgeport/MuSIC/C128_13)) and the other BAGs at the MEDICINE portal:  
 304 <https://labs-laboratory.com/medicine>.  
 305

306 **The polygenic risk scores of the 2024 MAEs**  
 307

308 Using the PRS-CS<sup>45</sup> method, we derived the PRS of the 2024 MAEs. We found that the 1799  
309 MAEs could significantly (P-value<0.05/2024) predict the phenotypic BAGs in the test/target  
310 data (split2 GWAS; detailed in **Method 3d**). Among these, 1791 brain MAEs resulted in  
311 significant incremental  $R^2$  ranging from 0.11% to 10.70% to predict the phenotype of interest.  
312 For example, the PSC (C1024\_593 for part of the cerebellum: [https://labs-  
313 laboratory.com/bridgeport/MuSIC/C1024\\_593](https://labs-laboratory.com/bridgeport/MuSIC/C1024_593)) showed an incremental of  $R^2$  10.70%. The renal  
314 BAG showed an incremental  $R^2$  of 5.92%, followed by the metabolic ( $R^2 = 5.67%$ ) and  
315 pulmonary BAG ( $R^2 = 3.86%$ ) (**Fig. 5a** and (**Supplementary eFile 8**)).

316 We then applied the model to the entire UKBB population and performed a PRS-wide  
317 association study (PWAS), where the 2024 PRS-MAEs were linked to the 59 phenotypes that  
318 were not initially used to compute the respective PRS, to avoid the circular bias<sup>46</sup>  
319 (**Supplementary eTable 5**). Refer to **Method 3d** for details. We found 388 significant  
320 associations (P-value<0.05/2024/59) between 7 PRS-MAEs and 41 phenotypes. Among these,  
321 PSC C32\_1 showed the most associations (94%); the lifestyle factor for only fish intake (Field  
322 ID: 16) was highly linked to multiple PRS-MAEs (16%). These results were expected because  
323 the 59 phenotypes (e.g., cognitive and mental traits) are primarily linked to the brain, and  
324 lifestyle factors were largely linked to multiple organ systems (**Fig. 5b** and **Supplementary  
325 eFile 9**). All derived PRS will be returned to UKBB and made available to the community.

326  
327



328  
 329 **Figure 5: The polygenic risk score of the 2024 MAEs and PWAS**  
 330 (a) The incremental  $R^2$  of the PRS derived by PRC-CS to predict the 2024 MAEs in the  
 331 target/test data (i.e., the split2 GWAS). The y-axis indicates the proportions of phenotypic  
 332 variation that the PRS can significantly and additionally explain (i.e., incremental  $R^2$ ). The x-axis  
 333 lists the 8 organ systems. For the brain, we showed the PRS distribution of the significant results  
 334 from the 1791 brain PRS-MAEs; the other organ systems only have one PRS-MAE. (b) The  
 335 PWAS links the PRS-MAEs to the 59 additional phenotypes not used to compute the PRS-MAE  
 336 in the entire UKBB sample ( $P$ -value $<0.05/2024/59$ ).  
 337



## 338 Discussion

339 This study expands previously established genetic atlases<sup>47,32</sup> by integrating AI-derived  
340 endophenotypes via the 2024 MAEs within the multi-organ framework solely through GWAS  
341 summary statistics. We demonstrate a promising avenue for advancing imaging genetic research  
342 in two key aspects: *i*) integrating AI in imaging genetics and *ii*) exploring human aging and  
343 disease through a multi-organ perspective.

344 By comprehensively depicting the genetic architecture of the 2024 MAEs, we showcased  
345 that AI endophenotypes supported the endophenotype hypothesis<sup>14,15</sup>, in which they showed  
346 lower polygenicity and weaker negative selection effects than the disease diagnosis. First, it may  
347 suggest that these intermediate phenotypes exist along the causal pathway, bridging the gap  
348 between underlying genetics and "exo-phenotypes" like cognitive decline or disease diagnoses in  
349 case/control studies, thus positioned closer to the core etiology and pathology. Secondly, many  
350 of these 2024 MAEs originated from *in vivo* imaging methodologies like magnetic resonance  
351 imaging (MRI). Consequently, they tend to exhibit reduced noise levels (i.e., a higher SNR) in  
352 capturing disease-related effects and are less susceptible to biases, such as misclassification<sup>48</sup>,  
353 case/control-covariate sample bias (e.g., studies matching comorbidities and other factors), and  
354 imbalanced case/control ratios, as evidenced in many GWASs in FinnGen. Especially for the  
355 former, binary traits have a threshold for disease classification, leading to the dichotomization of  
356 individuals into affected and unaffected categories. Thirdly, the 525 DEs often represent  
357 complex diseases highly influenced by multiple genetic and environmental factors. Their  
358 multifaceted nature, involving numerous genes with modest effects and environmental  
359 interactions<sup>49</sup>, can lead to a higher vulnerability to disease onset and clinical symptoms.  
360 Consistent with this observation, we previously also found that one AI- and imaging-derived  
361 subtype of Alzheimer's disease<sup>50</sup> (AD1), but not the binary disease diagnosis, was genetically  
362 correlated with brain age (GM- and WM-BAG)<sup>6</sup>.

363 We observed that brain MAEs were overall more polygenic than MAEs from other organ  
364 systems. Brain disorders are highly polygenic<sup>51</sup>. First, the brain is a highly complex organ with  
365 intricate functions, and disorders affecting it are likely influenced by a larger number of genetic  
366 variants<sup>12,52</sup>. Second, many brain disorders are multifaceted, involving various aspects of brain  
367 structure, function, and connectivity, which can be influenced by various genetic factors<sup>19</sup>.  
368 Additionally, the brain regulates many physiological processes throughout the body, so  
369 disruptions in its function can have widespread effects, potentially involving interactions with  
370 multiple organ systems<sup>4</sup>. In addition, we found that most of the brain MAEs showed negative  
371 selection signatures, including the 9 disease subtype DNEs and 4 brain BAGs; some of the brain  
372 PSCs showed a positive *S* estimate (e.g., for the occipital lobe and subcortical structure,  
373  $S=0.31\pm 0.09$ : [https://labs-laboratory.com/bridgeport/MuSIC/C32\\_18](https://labs-laboratory.com/bridgeport/MuSIC/C32_18)). The anticipated negative  
374 selection signatures of biological age across multiple organs and disease subtypes are expected to  
375 align with our prior findings, which revealed pervasive signatures of natural selection across a  
376 range of complex human traits and functional genomic categories. This negative selection  
377 signature prevents mutations with large deleterious effects from becoming frequent in the  
378 population<sup>53</sup>. The positive selection signatures identified in certain brain PSCs may suggest that  
379 positive selection may also play a role in shaping the genetic architecture of brain structural  
380 networks.

381 The MUTATE atlas uncovered both established and previously undiscovered interactions  
382 concerning human systemic diseases within individual organs and across diverse organ systems.  
383 For example, within the cardiovascular system, the AI-derived MAE, cardiovascular BAG

384 showed both substantial genetic correlation (**Fig. 2**) and bi-directional causality (**Fig. 3 and 4**)  
385 with multiple heart diseases, such as ischaemic heart disease<sup>54</sup>, heart failure<sup>55</sup>, and atrial  
386 fibrillation<sup>56</sup>. Similarly, pulmonary BAG was also causally linked to multiple diseases related to  
387 the lung and respiratory system, including COPD<sup>57</sup> and various forms of asthma<sup>58</sup>. Another  
388 organ-specific connection was observed in neurologic diseases, encompassing conditions such as  
389 AD<sup>59</sup> and various mental disorders<sup>60</sup> linked to several MAEs associated with the brain, notably  
390 several PSCs and WM-BAG. Cross-organ interplay was evidenced for several novel  
391 connections. For instance, the brain PSCs exhibited causal connections to conditions extending  
392 beyond the brain, such as ventral hernia and vein diseases, as well as systemic conditions, like  
393 various forms of diabetes affecting the entire body. In contrast, AD appears to causally impact  
394 multiple BAGs across various human organ systems, including the renal, immune, and metabolic  
395 systems. It's widely recognized that AD, being a complex condition, triggers detrimental effects  
396 that influence several human organ systems<sup>59,61</sup>. Our previous study used imaging genetics to  
397 investigate this multi-organ involvement along the disease continuum<sup>62</sup>. These results highlight  
398 the clinical relevance and interpretation of these AI endophenotypes to quantify individual-level  
399 organ health.

400 Emphasizing preventative strategies for specific chronic diseases is crucial to enhancing  
401 overall multi-organ health. Our MAEs present opportunities as novel instruments for selecting  
402 populations in clinical trials and facilitating therapeutic development. AD and various forms of  
403 diabetes exemplify disease endpoints significantly impacting multiple human organ systems. AD  
404 stands as the leading cause of dementia in older adults, presenting a persistent challenge in  
405 medicine despite numerous pharmacotherapeutic clinical trials. These trials have included  
406 interventions, such as anti-amyloid drugs<sup>63,64</sup> and anti-tau drugs<sup>65</sup>. The complexity and  
407 multifaceted nature of the underlying neuropathological processes may account for the lack of  
408 effective treatments. We call on the scientific community to embrace various mechanistic  
409 hypotheses to elucidate AD pathogenesis beyond amyloid and tau<sup>66,67</sup>. Likewise, the complexity  
410 of diabetes, with its various contributing factors, renders prevention challenging<sup>68</sup>. Moreover,  
411 diabetes often coexists with other chronic conditions affecting multiple organ systems, such as  
412 cardiovascular diseases, hypertension, and dyslipidemia<sup>69</sup>. Successful prevention strategies  
413 require a holistic approach, encompassing lifestyle adjustments, education, healthcare access,  
414 and societal considerations.

## 415 416 **Limitation**

417 This study presents several limitations. Primarily, our analyses were centered solely on GWAS  
418 summary statistics derived from individuals of European ancestries. Future investigations should  
419 extend these findings to diverse ethnic groups, particularly those that are underrepresented, to  
420 ascertain broader applicability. This necessitates the research community's commitment to  
421 embracing open science in AI and genetics. Secondly, the computational genomics statistical  
422 methods utilized in this research rely on several underlying statistical assumptions, which could  
423 potentially be violated and introduce bias. We mitigated bias by employing multiple  
424 methodologies to compute heritability, genetic correlation, and causality to address this concern.  
425 Additionally, we conducted thorough sensitivity checks, and the detailed results are provided  
426 accordingly. Finally, these MAEs originated from a singular biomedical data modality, such as  
427 MRI. Future investigations should explore utilizing AI across multi-omics data, such as  
428 integrating imaging and genetics<sup>70</sup>, to capture underlying disease effects more comprehensively.  
429

430 **Outlook**

431 In summary, we introduced the MUTATE genetic atlas to comprehensively comprehend the  
432 genetic architecture of AI endophenotypes and chronic diseases in multi-organ science. This  
433 investigation underscores the potential of integrating AI into genetic research and supports a  
434 comprehensive approach to investigating human diseases within a multi-organ paradigm.

## 435 **STAR \* Methods**

### 436 **Method 1: GWAS summary statistics**

437 The present study solely utilized GWAS summary statistics; no individual-level data were used.  
438 We downloaded the GWAS summary statistics from three web portals for the 2024 MAEs, 521  
439 DEs from FinnGen, and 4 DEs from PGC, respectively.

### 441 **UKBB**

442 UKBB is a population-based study of approximately 500,000 people recruited from the United  
443 Kingdom between 2006 and 2010. The UKBB study has ethical approval, and the ethics  
444 committee is detailed here: [https://www.ukbiobank.ac.uk/learn-more-about-uk-  
445 biobank/governance/ethics-advisory-committee](https://www.ukbiobank.ac.uk/learn-more-about-uk-biobank/governance/ethics-advisory-committee).

446 The GWAS summary statistics for all the 2024 MAEs are publicly available at the  
447 MEDICINE knowledge portal: <https://labs-laboratory.com/medicine>, which focuses on  
448 disseminating scientific findings on imaging genetics and AI methods in multi-organ science.  
449 Specifically, among the 2024 MAEs, 2003 PSCs – at varying scales from C32 to C1024 – were  
450 structural covariance networks derived via the sopNMF method<sup>12</sup>. 9 DNEs<sup>1</sup> captured the  
451 neuroanatomical heterogeneity of four brain diseases (AD1-2, ASD1-3, LLD1-2, and SCZ1-2)  
452 using semi-supervised clustering or representation learning methods<sup>42,62,71,72</sup>. 12 multi-organ  
453 BAGs (GM, WM, FC<sup>6</sup>, multimodal brain BAGs, cardiovascular BAG, eye BAG, hepatic BAG,  
454 immune BAG, musculoskeletal BAG, metabolic BAG, pulmonary BAG, and renal BAG<sup>73</sup>) were  
455 derived from various machine learning models to quantify the individual-level deviation from  
456 typical brain aging due to various pathological effects. Detailed AI methodologies are presented  
457 in **Method 2** for the MAEs, DNEs, and BAGs. All GWASs were performed within European  
458 ancestries and using the GRCh37 human genome assembly; the GWAS model (PLINK<sup>74</sup> for  
459 linear model and fastGWA<sup>75</sup> for linear mixed-effect model), sample sizes, and covariates  
460 included are detailed in the original papers and also in **Supplementary eTable 1a**.

461 Harmonization of GWAS summary statistics across different models and consortia for  
462 various software is crucial, such as aligning the effect allele and the direction of the effect size.  
463 There's currently no established standard in the field for this process, although some advice has  
464 been proposed<sup>76</sup>. Certain software harmonizes data based on the allele frequency of the effect  
465 allele, such as the *TwoSampleMR* package<sup>77</sup> for Mendelian randomization. In our UKBB MAE  
466 GWAS summary data, we harmonized the effect allele as the alternative allele from PLINK and  
467 A1 from fastGWA and provided its corresponding allele frequency. P-value, effect sizes (e.g.,  
468 BETA value and SE), and sample sizes are indicated too. The variant identifier is based on the rs  
469 ID number, not the chromosome number and position number combination.

### 471 **FinnGen**

472 The FinnGen<sup>22</sup> study is a research project based in Finland that explores combined genetics and  
473 health registry data to understand the underlying causes and mechanisms behind various disease  
474 endpoints. It particularly emphasizes the genetic basis of diseases in the Finnish population  
475 (>500,000) by conducting extensive GWAS and analyzing large-scale genomic data in  
476 collaboration with multiple research institutions and organizations. FinnGen has generously  
477 made their GWAS results publicly available to the community for research purposes  
478 ([https://www.finnngen.fi/en/access\\_results](https://www.finnngen.fi/en/access_results)).

479 The present study used the GWAS summary statistics version R9 released to the public  
480 on May 11, 2022, after harmonization by the consortium. In the R9 release, FinnGen analyzed  
481 2269 binary and 3 quantitative endpoints from 377,277 individuals and 20,175,454 variants.  
482 Regenie<sup>78</sup> was used to run the GWAS models, including sex, age, 10 PCs, and genotyping batch  
483 as covariates. Genotype imputation was done with the population-specific SISu v4.0 reference  
484 panel. In our analysis, we concentrated solely on binary DEs with case numbers exceeding 5000  
485 to ensure adequate statistical power, given the highly imbalanced case/control ratios. As the  
486 released data were based on the GRCh38 human genome assembly, we lifted the GWAS  
487 summary statistics to the GRCh37 version for all genetic analyses. **Supplementary eTable 1b**  
488 details the included 521 DEs. More details can be found at the FinnGen website:  
489 <https://finngen.gitbook.io/documentation/v/r9/>.

490 The FinnGen team has systematically harmonized the GWAS summary data for the 521  
491 DEs involved. The alternative allele serves as the effect allele. The rsID number represents the  
492 SNP; the chromosome number and position are also shared. The data includes P-values, effect  
493 sizes, and allele frequencies for both the alternative and reference alleles.

### 495 **Psychiatric Genomics Consortium**

496 PGC<sup>23</sup> is an international coalition of researchers exploring the genetic underpinnings of  
497 psychiatric disorders and beyond. This collaborative effort unites scientists globally to examine  
498 and decipher extensive genomic datasets concerning various brain diseases. The primary goal of  
499 PGC involves uncovering and comprehending the genetic elements that contribute to various  
500 psychiatric disorders, such as schizophrenia, bipolar disorder, and major depressive disorder. We  
501 downloaded GWAS summary statistics from the PGC website ([https://pgc.unc.edu/for-](https://pgc.unc.edu/for-researchers/download-results/)  
502 [researchers/download-results/](https://pgc.unc.edu/for-researchers/download-results/)) and manually harmonized the data to our Mendelian  
503 randomization analyses to replicate the FinnGen findings.

504 PGC did not harmonize the GWAS summary statistics; the available data information  
505 depends on each study. **Supplementary eTable 1c** details the 4 DEs (AD, ADHD, bipolar  
506 disorder, and schizophrenia) included after the data filtering procedure. First, we ensured that the  
507 study population comprised individuals of European ancestry and, if necessary, lifted the data to  
508 the human genome build assembly GRCh37. Secondly, we excluded two studies where the allele  
509 frequency is unavailable because the *TwoSampleMR* package<sup>77</sup> requires this information to  
510 harmonize the exposure and outcome data (e.g., flip the effect allele and effect size). Thirdly, we  
511 confirmed that the GWAS summary statistics didn't overlap with UKBB data. Specifically, the  
512 AD GWAS summary data<sup>79</sup> explicitly offered a version that excluded participants from UKBB.  
513 In addition, the original dataset lacked a column for the rsID number. To deal with this, we  
514 employed a mapping approach using the chromosome number and position to the dpSNP  
515 database (version 150), which allowed us to obtain the corresponding rsID numbers. All 4 DE  
516 GWAS summary data went through the same harmonization procedure as FinnGen (**Method 3c**)

### 517 518 519 **Method 2: 2024 multi-organ AI endophenotypes**

#### 520 **(a): The 2003 patterns of structural covariance of the brain**

521 In our earlier study<sup>12</sup>, we utilized the sopNMF method on an extensive and varied brain imaging  
522 MRI dataset ( $N=50,699$ , including data from UKBB) to generate the multi-scale brain PSCs. The  
523 scale C ranges from 32 to 1024, progressively increasing by a factor of 2; 11 PSCs vanished  
524 during models.



525 Biologically, the 2003 PSCs represent data-driven structural networks that co-vary across  
526 brain regions and individuals in a coordinated fashion. Mathematically, the sopNMF method is a  
527 stochastic approximation ("deep learning-analogy") constructed and extended based on  
528 opNMF<sup>80,81</sup>. Consider an imaging dataset comprising  $n$  images, each containing  $d$  voxels. We  
529 represent the data as a matrix  $X$ , where each column corresponds to a flattened image:  $X =$   
530  $[x_1, x_2, \dots, x_n]$ ,  $X \in \mathbb{R}_{\geq 0}^{d \times n}$ . The method factorizes  $X$  into two low-rank matrices  $W \in \mathbb{R}_{\geq 0}^{d \times r}$  and  
531  $H \in \mathbb{R}_{\geq 0}^{r \times n}$ , subject to two important constraints: *i*) non-negativity and *ii*) column-wise  
532 orthonormality. More mathematical details can be referred to the original references<sup>12,80,81</sup> and  
533 **Supplementary eMethod 2a**.

### 534 (b): The 9 dimensional neuroimaging endophenotypes of the brain

535 The nine DNEs captured the neuroanatomical heterogeneity of four brain diseases, including  
536 AD1-2 for AD<sup>62</sup>, ASD1-3 for autism spectrum disorder<sup>42</sup>, LLD1-2 for late-life depression<sup>71</sup>, and  
537 SCZ1-2 for schizophrenia<sup>72</sup>. The underlying AI methodologies involved two different semi-  
538 supervised clustering or representation learning algorithms: Surreal-GAN<sup>82</sup> and HYDRA<sup>83</sup>. Refer  
539 to a review for details of the semi-supervised learning<sup>84</sup>, which primarily seeks the so-called "*I-*  
540 *to-k*" mapping patterns or transformations from reference domains (like healthy controls) to  
541 target domains (such as patients).

542 Surreal-GAN<sup>82</sup> was used to derive AD1-2<sup>62</sup>. It unravels the intrinsic heterogeneity  
543 associated with diseases through a deep representation learning approach. The methodological  
544 innovation, compared to its preceptor Smile-GAN<sup>85</sup>, lies in how Surreal-GAN models disease  
545 heterogeneity: it interprets it as a continuous dimensional representation, ensures a consistent  
546 increase in disease severity within each dimension, and permits the simultaneous presence of  
547 multiple dimensions within the same participant without exclusivity. More mathematical details  
548 are presented in **Supplementary eMethod 2b**.

549 HYDRA<sup>83</sup> was employed to derive the other 7 DNEs. It utilizes a widely adopted  
550 discriminative technique, namely support vector machines (SVM), to establish the "*I-to-k*"  
551 mapping. The model extends multiple linear SVMs to the nonlinear domain by piecing them  
552 together. This approach serves the dual purpose of classification and clustering simultaneously.  
553 Specifically, it creates a convex polytope by amalgamating hyperplanes derived from  $k$  linear  
554 SVMs. This polytope separates the healthy control group from the  $k$  subpopulations within the  
555 patient group. Conceptually, each face of this convex polytope can be likened to encoding each  
556 subtype (categorical trait) or dimension (continuous trait), capturing distinctive disease effects  
557 (Refer to **Supplementary eMethod 2c**).

### 558 (c): The 12 biological age gaps of nine human organ systems

559 The nine multi-organ BAGs (brain, cardiovascular, eye, hepatic, immune, musculoskeletal,  
560 metabolic, pulmonary, and renal) were derived from a previous study<sup>5</sup> that used AI to predict the  
561 chronological age of healthy individuals without chronic medical conditions: AI-predicted age –  
562 chronological age. Using a 20-fold cross-validation procedure, we applied the model for each  
563 organ system, employing a linear support vector machine. Before training each model iteration,  
564 standardization was applied to measures (excluding categorical variables) within the training set.  
565 The model was solved using sequential minimal optimization with a gap tolerance of 0.001. The  
566 support vector regression settings were adjusted for optimization, adhering to established  
567 principles in the field<sup>86</sup>.

570           Alongside the nine organ BAGs, we previously derived three multimodal brain BAGs  
571 (GM, WM, and FC-IDP) using features from gray matter (GM), white matter (WM), and  
572 functional connectivity (FC) in MRI scans<sup>6</sup>. We systematically compared four machine learning  
573 models: SVR, LASSO regression, multilayer perceptron, and a five-layer neural network. We  
574 employed nested cross-validation (CV) and included an independent test dataset<sup>87</sup> for a fair  
575 comparison across different models and MRI modalities. This process involved an outer loop CV  
576 with 100 repeated random splits: 80% for training and validation and 20% for testing. Within the  
577 inner loop, a 10-fold CV was utilized for hyperparameter tuning. Furthermore, we reserved an  
578 independent test dataset, which was kept unseen until the fine-tuning of the machine learning  
579 models<sup>88</sup> (e.g., hyperparameters for SVR) was completed.  
580

### 581 **Method 3: Genetic analyses based on GWAS summary statistics**

#### 582 **(a): The genetic architecture of the 2024 MAEs and 525 DEs**

583           Primarily, we used SBayesS<sup>39</sup> to estimate three sets of parameters that fully unveil the genetic  
584 architecture of the 2024 MAEs and 525 DEs. SBayesS is an expanded approach capable of  
585 estimating three essential parameters characterizing the genetic architecture of complex traits  
586 through a Bayesian mixed linear model<sup>89</sup>. This method only requires GWAS summary statistics  
587 of the SNPs and LD information from a reference sample. These parameters include SNP-based  
588 heritability ( $h_{SNP}^2$ ), polygenicity ( $\pi$ ), and the relationship between minor allele frequency (MAF)  
589 and effect size ( $S$ ). We used the software pre-computed sparse LD correlation matrix derived  
590 from the European ancestry by Zeng et al.<sup>39</sup>. More mathematical details can be found in the  
591 original paper from Zeng et al.<sup>39</sup>. We ran the *gctb* command<sup>89</sup> using the argument *--sbayes S*, and  
592 left all other arguments by default. When applying SBayesS to the 2025 MAEs and 525 DEs  
593 summary data, we found that 18 DEs failed to converge in the MCMC sampling, which may be  
594 due to LD differences between FinnGen and UKBB samples (the latter was used as the LD  
595 reference in SBayesS).

596           To benchmark different methods used in the field for SNP-based heritability estimates,  
597 we also employed two other methods based on GWAS summary data: *i*) LDSC<sup>28</sup> and *ii*)  
598 SumHer<sup>33</sup>. LDSC relies on the principle that the correlation between SNP effect sizes and  
599 linkage disequilibrium with neighboring SNPs can be used to estimate the proportion of  
600 heritability explained by all SNPs using GWAS summary data. For LDSC, we used the  
601 precomputed LD scores from the 1000 Genomes of European ancestry. All other parameters  
602 were set to default in the software. After merging the GWAS summary statistics, we chose the  
603 1000 Genomes reference panel for fair comparisons between the two studies and ensured that  
604 most SNPs were included in the analyses. For example, for the DE  
605 (RX\_PARACETAMOL\_NSAID), after merging with the reference panel LD, 1,171,361  
606 remained. For the first MAE (C32\_1), 1,092,510 SNPs remained after the same merging  
607 procedure. Furthermore, FinnGen didn't provide the original genotype data; they only shared the  
608 LD information via the LDstore software but did not provide the allele information.  
609 Consequently, we cannot generate in-sample LD scores using the LDSC software. Finally, a  
610 prior investigation<sup>90</sup> showcased the robustness of LDSC concerning the selection of LD  
611 reference panels – multi-ethnic European, Finnish-only, non-Finnish European from 1000  
612 Genomes Phase 3 data, and FINRISK Finnish reference panel – regarding heritability estimates  
613 in four lipid traits within a Finnish population.

614 For SumHer, we used the BLD-LDAK model, as the software suggested. BLD-LDAK  
615 stands for "Bayesian LD-adjusted Kinship," where LD-adjusted kinship refers to the calculation  
616 of genetic relatedness between individuals using information about the correlation of alleles  
617 between nearby SNPs (linkage disequilibrium). We used the software-provided tagging file,  
618 generated from 2000 white British individuals, as a reference panel suggested by the software for  
619 European ancestry groups. The HapMap3 data ([https://www.broadinstitute.org/medical-and-](https://www.broadinstitute.org/medical-and-population-genetics/hapmap-3)  
620 [population-genetics/hapmap-3](https://www.broadinstitute.org/medical-and-population-genetics/hapmap-3)) merged with the tested GWAS summary SNPs. Similarly, we  
621 ensured sufficient SNPs remained after merging with the reference panel. All other parameters  
622 were set to default. SumHer differs from LDSC in several ways: *i*) it models inflation  
623 multiplicatively, whereas LDSC uses an additive approach; *ii*) it accounts for uneven LD patterns  
624 and incorporates MAF on SNP effect; and *iii*) it utilizes a restricted maximum likelihood  
625 solver rather than regression to estimate the  $h_{SNP}^2$ .

626  
627 **(b): Genetic correlation:** We used three different methods to compute the MAE-DE pairwise  
628 ( $N=2024 \times 525=1,062,600$ ) genetic correlations ( $r_g$ ): *i*) LDSC<sup>28</sup>, *ii*) GNOVA<sup>34</sup>, and *iii*) HDL<sup>38</sup>.

629 An earlier study<sup>92</sup> highlighted the significance of selecting an appropriate LD score  
630 reference panel for genetic correlation estimates based on summary statistics. We generated the  
631 same reference panel for LD scores across the three software for a fair comparison. For LDSC,  
632 we used the precomputed LD scores from the 1000 Genomes of European ancestry provided by  
633 the software. All other parameters were set by default. To employ GNOVA, we created the LD  
634 scores utilizing the 1000 Genomes of European ancestry using the `--save-ld` argument within the  
635 `gnova.py` script. For HDL, we used the provided scripts from HDL to generate the LD scores  
636 using the same 1000 Genomes of European ancestry  
637 (<https://github.com/zhenin/HDL/wiki/Build-a-reference-panel>).

638 Through our analysis, we found that the three packages have different levels of model  
639 convergence rates, which is critical for future applications as these open-source packages claim  
640 to advance genetic research. In particular, we found that LDSC (1,062,577/1,062,600) and  
641 GNOVA (1,062,600/1,062,600) converged for most of the tested MAE-DE pairs, whereas HDL  
642 failed a substantial proportion of the analyses, leading to only 59,291 out of the 1,062,600 MAE-  
643 DE pairs (refer to the raised issue: <https://github.com/zhenin/HDL/issues/30>). Therefore, in **Fig.**  
644 **2**, we presented common significant results after Bonferroni corrections from the LDSC and  
645 GNOVA, resulting in 133 and 45 significant signals corrected on *i*) the number of MAEs and *ii*)  
646 the number of MAEs and DEs.

647  
648 **(c): Two-sample bidirectional Mendelian randomization:** We employed a bidirectional, two-  
649 sample Mendelian randomization using the *TwoSampleMR* package<sup>77</sup> to infer the causal  
650 relationships between the 2024 MAEs, 521 DEs from FinnGen, and 4 brain DEs from PGC.

651 The forward Mendelian randomization examined causality from the 2024 MAEs to the  
652 525 DEs, while the inverse analysis investigated causality from the 525 DEs to the 2024 MAEs.  
653 The *TwoSampleMR* package<sup>77</sup> applied five different Mendelian randomization methods. We  
654 presented the significant findings after the Bonferroni correction using the inverse variance  
655 weighted (IVW) estimator, verifying that the correction remained significant in at least one of  
656 the other four estimators (Egger, weighted median, simple mode, and weighted mode  
657 estimators). For the significant signals, we performed several sensitivity analyses. First, a  
658 heterogeneity test was performed to check for violating the IV assumptions. Horizontal  
659 pleiotropy was estimated to navigate the violation of the IV's exclusivity assumption<sup>93</sup> using a



660 funnel plot, single-SNP Mendelian randomization approaches, and Mendelian randomization  
661 Egger estimator. Moreover, the leave-one-out analysis excluded one instrument (SNP) at a time  
662 and assessed the sensitivity of the results to individual SNP.

663 Critically, to enhance transparency and reproducibility, we followed a systematic  
664 procedure guided by the STROBE-MR Statement<sup>94</sup> in conducting all causality analyses. This  
665 comprehensive approach encompassed the selection of exposure and outcome variables,  
666 reporting full sets of statistics, and implementing sensitivity checks to identify potential  
667 violations of underlying assumptions. First, we performed an unbiased quality check on the  
668 GWAS summary statistics. Notably, the absence of population overlapping bias<sup>29</sup> was  
669 confirmed, given that FinnGen and UKBB participants largely represent European ancestry  
670 populations without explicit overlap. For the four PGC DEs, we ensured that no UKBB  
671 participants were included in the GWAS summary data. Furthermore, all GWAS summary  
672 statistics were based on or lifted to GRCh37. Subsequently, we selected the effective exposure  
673 variables by assessing the statistical power of the exposure GWAS summary statistics in terms of  
674 instrumental variables (IVs), ensuring that the number of IVs exceeded 8 before harmonizing the  
675 data. Crucially, the function "*clump\_data*" was applied to the exposure GWAS data, considering  
676 LD. The function "*harmonise\_data*" was then used to harmonize the GWAS summary statistics  
677 of the exposure and outcome variables. This overall resulted in a smaller number (< 525 DEs or  
678 2024 MAEs) of effective exposure/outcome variables in both forward and inverse Mendelian  
679 randomization analyses, as certain GWAS summary data did not have enough IVs.

680  
681 **(d): PRS calculation:** PRS calculation used the GWAS summary statistics from the split-sample  
682 sensitivity analysis from our previous studies<sup>12,6,4,1</sup>. We established PRS weights using split1  
683 GWAS data as the base/training set, while the split2 GWAS summary statistics were used as the  
684 target/testing data. Details of the quality control (QC) procedures are shown in our previous  
685 studies<sup>12,6,4,1</sup>. Following the QC procedures, PRS for the split2 group was computed using PRS-  
686 CS<sup>45</sup>. PRS-CS infers posterior SNP effect sizes under continuous shrinkage priors using GWAS  
687 summary statistics and an LD reference panel (i.e., UKBB reference). To ascertain the most  
688 suitable PRS, we conducted a linear regression encompassing different P-value thresholds  
689 (0.001, 0.05, 0.1, 0.2, 0.3, 0.4, 0.5), while controlling for age, sex, intracranial volume (if  
690 applicable), and the forty genetic principal components. The optimal P-value threshold for PRS-  
691 MAE was determined based on the highest incremental  $R^2$ .

692 After determining the optimal model, we applied the model to the entire UKBB sample  
693 (~500k individuals). We then performed a PWAS to link the 2024 PRS-MAEs and 59 additional  
694 phenotypes (**Supplementary eTable 5**) not used to compute the PRS-MAE to avoid the circular  
695 bias<sup>46</sup>. The 59 phenotypes include cognitive scores (e.g., fluid intelligence score; Field ID:  
696 20016, mental traits (e.g., fed-up feelings; Filed ID: 1960), and lifestyle factors (e.g., tea intake;  
697 Filed ID: 1488). A linear regression was built considering the following covariates: sex (Field  
698 ID: 31), smoking status (Field ID: 20116), weight (Field ID: 21002), standing height (Field ID:  
699 50), waist circumference (Field ID: 48), age at recruitment (Field ID: 21022), and first 40 genetic  
700 principal components (Field ID: 22009).

701  
702

## 703 **Data Availability**

704 The results of the MUTATE atlas are disseminated at the MUTATE knowledge portal:  
705 <https://labs-laboratory.com/mutate>. The GWAS summary statistics for the 2024 MAEs can be  
706 accessed publicly through the MEDICINE knowledge portal: [https://labs-](https://labs-laboratory.com/medicine)  
707 [laboratory.com/medicine](https://labs-laboratory.com/medicine) and the BRIDGEPORT knowledge portal: [https://labs-](https://labs-laboratory.com/bridgeport)  
708 [laboratory.com/bridgeport](https://labs-laboratory.com/bridgeport). The GWAS summary statistics for the 521 DEs from FinnGen are  
709 publicly available at: <https://finngen.gitbook.io/documentation/v/r9/>. The GWAS summary  
710 statistics for the 4 DEs from PGC are publicly available at: [https://pgc.unc.edu/for-](https://pgc.unc.edu/for-researchers/download-results/)  
711 [researchers/download-results/](https://pgc.unc.edu/for-researchers/download-results/). The study used only GWAS summary statistics rather than  
712 individual-level data from the UK Biobank. However, the 2024 MAE GWAS data was initially  
713 derived from previous studies conducted under Application Numbers 35148 and 60698 from the  
714 UK Biobank.

## 715 **Code Availability**

716 The software and resources used in this study are all publicly available:

- 717 • *GCTB*: <https://cnsgenomics.com/software/gctb/#Overview>, SNP-based heritability,  
718 polygenicity, and MAF/effect size ratio
- 719 • *LDSC*: <https://github.com/bulik/ldsc>, SNP-based heritability and genetic correlation
- 720 • *SumHer*: <https://dougspeed.com/sumher/>, SNP-based heritability
- 721 • *GNOVA*: <https://github.com/xtonyjiang/GNOVA>, genetic correlation
- 722 • *HDL*: <https://github.com/zhenin/HDL>, genetic correlation
- 723 • *TwoSampleMR*: <https://mrcieu.github.io/TwoSampleMR/index.html>, Mendelian  
724 randomization
- 725 • PRS-CS: <https://github.com/getian107/PRScs>, PRS  
726

727 **Competing Interests**

728 None

729

730 **Authors' contributions**

731 Dr. Wen has full access to all the study data and is responsible for its integrity and accuracy.

732 *Study concept and design:* W.J

733 *Acquisition, analysis, or interpretation of data:* W.J

734 *Drafting of the manuscript:* W.J

735 *Critical revision of the manuscript for important intellectual content:* All authors

736 *Statistical analysis:* W.J

## 737 **References**

- 738 1. Wen, J. *et al.* Neuroimaging-AI Endophenotypes of Brain Diseases in the General  
739 Population: Towards a Dimensional System of Vulnerability. 2023.08.16.23294179  
740 Preprint at <https://doi.org/10.1101/2023.08.16.23294179> (2023).
- 741 2. Trubetskoy, V. *et al.* Mapping genomic loci implicates genes and synaptic biology in  
742 schizophrenia. *Nature* **604**, 502–508 (2022).
- 743 3. Kendler, K. & Neale, M. Endophenotype: a conceptual analysis. *Mol Psychiatry* **15**, 789–  
744 797 (2010).
- 745 4. Wen, J. *et al.* The Genetic Architecture of Biological Age in Nine Human Organ Systems.  
746 *medRxiv* 2023.06.08.23291168 (2023) doi:10.1101/2023.06.08.23291168.
- 747 5. Tian, Y. E. *et al.* Heterogeneous aging across multiple organ systems and prediction of  
748 chronic disease and mortality. *Nat Med* 1–11 (2023) doi:10.1038/s41591-023-02296-6.
- 749 6. Wen, J. *et al.* The genetic architecture of multimodal human brain age. *Nat Commun* **15**,  
750 2604 (2024).
- 751 7. Zhao, B. *et al.* Heart-brain connections: Phenotypic and genetic insights from magnetic  
752 resonance images. *Science* **380**, abn6598 (2023).
- 753 8. McCracken, C. *et al.* Multi-organ imaging demonstrates the heart-brain-liver axis in UK  
754 Biobank participants. *Nat Commun* **13**, 7839 (2022).
- 755 9. Nie, C. *et al.* Distinct biological ages of organs and systems identified from a multi-omics  
756 study. *Cell Reports* **38**, 110459 (2022).
- 757 10. Liu, Y. *et al.* Genetic architecture of 11 organ traits derived from abdominal MRI using  
758 deep learning. *eLife* **10**, e65554 (2021).

- 759 11. Oh, H. S.-H. *et al.* Organ aging signatures in the plasma proteome track health and disease.  
760 *Nature* **624**, 164–172 (2023).
- 761 12. Wen, J. *et al.* Genomic loci influence patterns of structural covariance in the human brain.  
762 *Proceedings of the National Academy of Sciences* **120**, e2300842120 (2023).
- 763 13. Hodson, R. Precision medicine. *Nature* **537**, S49–S49 (2016).
- 764 14. Gottesman, I. I. & Gould, T. D. The endophenotype concept in psychiatry: etymology and  
765 strategic intentions. *Am J Psychiatry* **160**, 636–645 (2003).
- 766 15. Cannon, T. D. & Keller, M. C. Endophenotypes in the Genetic Analyses of Mental  
767 Disorders. *Annual Review of Clinical Psychology* **2**, 267–290 (2006).
- 768 16. Rajpurkar, P., Chen, E., Banerjee, O. & Topol, E. J. AI in health and medicine. *Nat Med* **28**,  
769 31–38 (2022).
- 770 17. Bycroft, C. *et al.* The UK Biobank resource with deep phenotyping and genomic data.  
771 *Nature* **562**, 203–209 (2018).
- 772 18. Miller, K. L. *et al.* Multimodal population brain imaging in the UK Biobank prospective  
773 epidemiological study. *Nature Neuroscience* **19**, 1523–1536 (2016).
- 774 19. Elliott, L. T. *et al.* Genome-wide association studies of brain imaging phenotypes in UK  
775 Biobank. *Nature* **562**, 210–216 (2018).
- 776 20. Sun, B. B. *et al.* Plasma proteomic associations with genetics and health in the UK  
777 Biobank. *Nature* **622**, 329–338 (2023).
- 778 21. Dhindsa, R. S. *et al.* Rare variant associations with plasma protein levels in the UK  
779 Biobank. *Nature* **622**, 339–347 (2023).
- 780 22. Kurki, M. I. *et al.* FinnGen provides genetic insights from a well-phenotyped isolated  
781 population. *Nature* **613**, 508–518 (2023).

- 782 23. O'Donovan, M. C. What have we learned from the Psychiatric Genomics Consortium.  
783 *World Psychiatry* **14**, 291–293 (2015).
- 784 24. Buniello, A. *et al.* The NHGRI-EBI GWAS Catalog of published genome-wide association  
785 studies, targeted arrays and summary statistics 2019. *Nucleic Acids Res* **47**, D1005–D1012  
786 (2019).
- 787 25. Elsworth, B. *et al.* The MRC IEU OpenGWAS data infrastructure. 2020.08.10.244293  
788 Preprint at <https://doi.org/10.1101/2020.08.10.244293> (2020).
- 789 26. Watanabe, K. *et al.* A global overview of pleiotropy and genetic architecture in complex  
790 traits. *Nat Genet* **51**, 1339–1348 (2019).
- 791 27. Shen, L. & Thompson, P. M. Brain Imaging Genomics: Integrated Analysis and Machine  
792 Learning. *Proceedings of the IEEE* **108**, 125–162 (2020).
- 793 28. Bulik-Sullivan, B. K. *et al.* LD Score regression distinguishes confounding from  
794 polygenicity in genome-wide association studies. *Nat Genet* **47**, 291–295 (2015).
- 795 29. Sanderson, E. *et al.* Mendelian randomization. *Nat Rev Methods Primers* **2**, 1–21 (2022).
- 796 30. Bowden, J., Davey Smith, G. & Burgess, S. Mendelian randomization with invalid  
797 instruments: effect estimation and bias detection through Egger regression. *Int J Epidemiol*  
798 **44**, 512–525 (2015).
- 799 31. Open science. *Nature* **550**, 7–8 (2017).
- 800 32. Bulik-Sullivan, B. *et al.* An atlas of genetic correlations across human diseases and traits.  
801 *Nat Genet* **47**, 1236–1241 (2015).
- 802 33. Speed, D. & Balding, D. J. SumHer better estimates the SNP heritability of complex traits  
803 from summary statistics. *Nat Genet* **51**, 277–284 (2019).



- 804 34. Lu, Q. *et al.* A Powerful Approach to Estimating Annotation-Stratified Genetic Covariance  
805 via GWAS Summary Statistics. *The American Journal of Human Genetics* **101**, 939–964  
806 (2017).
- 807 35. Smith, G. D. & Ebrahim, S. ‘Mendelian randomization’: can genetic epidemiology  
808 contribute to understanding environmental determinants of disease? *Int J Epidemiol* **32**, 1–  
809 22 (2003).
- 810 36. Davey Smith, G. & Hemani, G. Mendelian randomization: genetic anchors for causal  
811 inference in epidemiological studies. *Hum Mol Genet* **23**, R89-98 (2014).
- 812 37. Pierce, B. L. & Burgess, S. Efficient design for Mendelian randomization studies:  
813 subsample and 2-sample instrumental variable estimators. *Am J Epidemiol* **178**, 1177–1184  
814 (2013).
- 815 38. Ning, Z., Pawitan, Y. & Shen, X. High-definition likelihood inference of genetic  
816 correlations across human complex traits. *Nat Genet* **52**, 859–864 (2020).
- 817 39. Zeng, J. *et al.* Widespread signatures of natural selection across human complex traits and  
818 functional genomic categories. *Nat Commun* **12**, 1164 (2021).
- 819 40. Evans, L. M. *et al.* Comparison of methods that use whole genome data to estimate the  
820 heritability and genetic architecture of complex traits. *Nat Genet* **50**, 737–745 (2018).
- 821 41. Ojavee, S. E., Kutalik, Z. & Robinson, M. R. Liability-scale heritability estimation for  
822 biobank studies of low-prevalence disease. *The American Journal of Human Genetics* **109**,  
823 2009–2017 (2022).
- 824 42. Hwang, G. *et al.* Assessment of Neuroanatomical Endophenotypes of Autism Spectrum  
825 Disorder and Association With Characteristics of Individuals With Schizophrenia and the  
826 General Population. *JAMA Psychiatry* (2023) doi:10.1001/jamapsychiatry.2023.0409.

- 827 43. Makowski, C. *et al.* Discovery of genomic loci of the human cerebral cortex using  
828 genetically informed brain atlases. *8* (2022).
- 829 44. Matoba, N., Love, M. I. & Stein, J. L. Evaluating brain structure traits as endophenotypes  
830 using polygenicity and discoverability. *Human Brain Mapping* **43**, 329–340 (2022).
- 831 45. Ge, T., Chen, C.-Y., Ni, Y., Feng, Y.-C. A. & Smoller, J. W. Polygenic prediction via  
832 Bayesian regression and continuous shrinkage priors. *Nat Commun* **10**, 1776 (2019).
- 833 46. Kriegeskorte, N., Simmons, W. K., Bellgowan, P. S. F. & Baker, C. I. Circular analysis in  
834 systems neuroscience: the dangers of double dipping. *Nat. Neurosci.* **12**, 535–540 (2009).
- 835 47. Sakaue, S. *et al.* A cross-population atlas of genetic associations for 220 human  
836 phenotypes. *Nat Genet* **53**, 1415–1424 (2021).
- 837 48. Lee, S. H. *et al.* Genetic relationship between five psychiatric disorders estimated from  
838 genome-wide SNPs. *Nat Genet* **45**, 984–994 (2013).
- 839 49. Hunter, D. J. Gene–environment interactions in human diseases. *Nat Rev Genet* **6**, 287–298  
840 (2005).
- 841 50. Wen, J. *et al.* Genetic, clinical underpinnings of subtle early brain change along  
842 Alzheimer’s dimensions. 2022.09.16.508329 Preprint at  
843 <https://doi.org/10.1101/2022.09.16.508329> (2022).
- 844 51. THE BRAINSTORM CONSORTIUM *et al.* Analysis of shared heritability in common  
845 disorders of the brain. *Science* **360**, eaap8757 (2018).
- 846 52. Smith, S. M. *et al.* An expanded set of genome-wide association studies of brain imaging  
847 phenotypes in UK Biobank. *Nat Neurosci* **24**, 737–745 (2021).
- 848 53. Walsh, B. & Lynch, M. *Evolution and Selection of Quantitative Traits*. (Oxford University  
849 Press, 2018).

- 850 54. Plackett, B. A graphical guide to ischaemic heart disease. *Nature* **594**, S3–S3 (2021).
- 851 55. Peisker, F. *et al.* Mapping the cardiac vascular niche in heart failure. *Nat Commun* **13**, 3027  
852 (2022).
- 853 56. Brundel, B. J. J. M. *et al.* Atrial fibrillation. *Nat Rev Dis Primers* **8**, 1–23 (2022).
- 854 57. Barnes, P. J. *et al.* Chronic obstructive pulmonary disease. *Nat Rev Dis Primers* **1**, 1–21  
855 (2015).
- 856 58. Holgate, S. T. *et al.* Asthma. *Nat Rev Dis Primers* **1**, 1–22 (2015).
- 857 59. Ballard, C. *et al.* Alzheimer’s disease. *The Lancet* **377**, 1019–1031 (2011).
- 858 60. Marshall, M. The hidden links between mental disorders. *Nature* **581**, 19–21 (2020).
- 859 61. Eiser, A. R. & Fulop, T. Alzheimer’s Disease Is a Multi-Organ Disorder: It May Already  
860 Be Preventable. *J Alzheimers Dis* **91**, 1277–1281 (2023).
- 861 62. Wen, J. *et al.* Genetic, clinical underpinnings of subtle early brain change along  
862 Alzheimer’s dimensions. 2022.09.16.508329 Preprint at  
863 <https://doi.org/10.1101/2022.09.16.508329> (2022).
- 864 63. Guthrie, H. *et al.* Safety, Tolerability, and Pharmacokinetics of Crenezumab in Patients  
865 with Mild-to-Moderate Alzheimer’s Disease Treated with Escalating Doses for up to  
866 133 Weeks. *J Alzheimers Dis* **76**, 967–979 (2020).
- 867 64. Sevigny, J. *et al.* The antibody aducanumab reduces A $\beta$  plaques in Alzheimer’s disease.  
868 *Nature* **537**, 50–56 (2016).
- 869 65. Congdon, E. E. & Sigurdsson, E. M. Tau-targeting therapies for Alzheimer disease. *Nat Rev*  
870 *Neurol* **14**, 399–415 (2018).
- 871 66. Jack, C. R. *et al.* Tracking pathophysiological processes in Alzheimer’s disease: an updated  
872 hypothetical model of dynamic biomarkers. *Lancet Neurol* **12**, 207–216 (2013).

- 873 67. Frisoni, G. B. *et al.* The probabilistic model of Alzheimer disease: the amyloid hypothesis  
874 revised. *Nat Rev Neurosci* **23**, 53–66 (2022).
- 875 68. Tomic, D., Shaw, J. E. & Magliano, D. J. The burden and risks of emerging complications  
876 of diabetes mellitus. *Nat Rev Endocrinol* **18**, 525–539 (2022).
- 877 69. DeFronzo, R. A. *et al.* Type 2 diabetes mellitus. *Nat Rev Dis Primers* **1**, 1–22 (2015).
- 878 70. Yang, Z. *et al.* Gene-SGAN: discovering disease subtypes with imaging and genetic  
879 signatures via multi-view weakly-supervised deep clustering. *Nat Commun* **15**, 354 (2024).
- 880 71. Wen, J. *et al.* Characterizing Heterogeneity in Neuroimaging, Cognition, Clinical  
881 Symptoms, and Genetics Among Patients With Late-Life Depression. *JAMA Psychiatry*  
882 (2022) doi:10.1001/jamapsychiatry.2022.0020.
- 883 72. Chand, G. B. *et al.* Two distinct neuroanatomical subtypes of schizophrenia revealed using  
884 machine learning. *Brain* **143**, 1027–1038 (2020).
- 885 73. Wen, J. *et al.* The Genetic Architecture of Biological Age in Nine Human Organ Systems.  
886 *medRxiv* 2023.06.08.23291168 (2023) doi:10.1101/2023.06.08.23291168.
- 887 74. Purcell, S. *et al.* PLINK: A Tool Set for Whole-Genome Association and Population-Based  
888 Linkage Analyses. *Am J Hum Genet* **81**, 559–575 (2007).
- 889 75. Jiang, L. *et al.* A resource-efficient tool for mixed model association analysis of large-scale  
890 data. *Nat Genet* **51**, 1749–1755 (2019).
- 891 76. MacArthur, J. A. L. *et al.* Workshop proceedings: GWAS summary statistics standards and  
892 sharing. *Cell Genomics* **1**, (2021).
- 893 77. Hemani, G. *et al.* The MR-Base platform supports systematic causal inference across the  
894 human phenome. *eLife* **7**, e34408 (2018).

- 895 78. Mbatchou, J. *et al.* Computationally efficient whole-genome regression for quantitative and  
896 binary traits. *Nat Genet* **53**, 1097–1103 (2021).
- 897 79. Wightman, D. P. *et al.* A genome-wide association study with 1,126,563 individuals  
898 identifies new risk loci for Alzheimer’s disease. *Nat Genet* **53**, 1276–1282 (2021).
- 899 80. Sotiras, A., Resnick, S. M. & Davatzikos, C. Finding imaging patterns of structural  
900 covariance via Non-Negative Matrix Factorization. *NeuroImage* **108**, 1–16 (2015).
- 901 81. Zhirong Yang & Oja, E. Linear and Nonlinear Projective Nonnegative Matrix  
902 Factorization. *IEEE Trans. Neural Netw.* **21**, 734–749 (2010).
- 903 82. Yang, Z., Wen, J. & Davatzikos, C. Surreal-GAN:Semi-Supervised Representation  
904 Learning via GAN for uncovering heterogeneous disease-related imaging patterns. *ICLR*  
905 (2021).
- 906 83. Varol, E., Sotiras, A. & Davatzikos, C. HYDRA: Revealing heterogeneity of imaging and  
907 genetic patterns through a multiple max-margin discriminative analysis framework.  
908 *NeuroImage* **145**, 346–364 (2017).
- 909 84. Wen, J. *et al.* Subtyping Brain Diseases from Imaging Data. in *Machine Learning for Brain*  
910 *Disorders* (ed. Colliot, O.) 491–510 (Springer US, New York, NY, 2023). doi:10.1007/978-  
911 1-0716-3195-9\_16.
- 912 85. Yang, Z. *et al.* A deep learning framework identifies dimensional representations of  
913 Alzheimer’s Disease from brain structure. *Nat Commun* **12**, 7065 (2021).
- 914 86. Chang, C.-C. & Lin, C.-J. LIBSVM: A library for support vector machines. *ACM Trans.*  
915 *Intell. Syst. Technol.* **2**, 1–27 (2011).

- 916 87. Samper-González, J. *et al.* Reproducible evaluation of classification methods in  
917 Alzheimer's disease: Framework and application to MRI and PET data. *NeuroImage* **183**,  
918 504–521 (2018).
- 919 88. Wen, J. *et al.* Convolutional neural networks for classification of Alzheimer's disease:  
920 Overview and reproducible evaluation. *Medical Image Analysis* **63**, 101694 (2020).
- 921 89. Zeng, J. *et al.* Signatures of negative selection in the genetic architecture of human complex  
922 traits. *Nat Genet* **50**, 746–753 (2018).
- 923 90. Hautakangas, H. LD Score regression for estimating and partitioning heritability of lipid  
924 levels in the Finnish population. (University of Helsinki, Helsinki, 2018).
- 925 91. Speed, D., Holmes, J. & Balding, D. J. Evaluating and improving heritability models using  
926 summary statistics. *Nat Genet* **52**, 458–462 (2020).
- 927 92. Zhang, Y. *et al.* Comparison of methods for estimating genetic correlation between  
928 complex traits using GWAS summary statistics. *Brief Bioinform* **22**, bbaa442 (2021).
- 929 93. Bowden, J. *et al.* A framework for the investigation of pleiotropy in two-sample summary  
930 data Mendelian randomization. *Stat Med* **36**, 1783–1802 (2017).
- 931 94. Skrivankova, V. W. *et al.* Strengthening the Reporting of Observational Studies in  
932 Epidemiology Using Mendelian Randomization: The STROBE-MR Statement. *JAMA* **326**,  
933 1614–1621 (2021).
- 934

935 **Acknowledgment**

936 We sincerely thank the UK Biobank (<https://www.ukbiobank.ac.uk/>), FinnGen  
937 (<https://www.finngen.fi/en>), and PGC (<https://pgc.unc.edu/>) team for their invaluable  
938 contribution to advancing clinical research in our field.